Gene therapy and genetic engineering are transforming the landscape of personalized and regenerative medicine by offering precise, targeted corrections at the genetic level. These technologies enable the replacement, repair, or regulation of defective genes using viral or non-viral delivery systems, significantly altering the course of inherited and acquired diseases. In tissue engineering, gene editing plays a pivotal role in programming stem cells, enhancing scaffold-cell interactions, and boosting tissue regeneration. Breakthroughs such as CRISPR-Cas9, base editing, and prime editing allow high-fidelity genomic modifications, minimizing off-target effects and increasing clinical feasibility. Gene therapy and genetic engineering are also being integrated into smart biomaterial systems and synthetic biology platforms to provide controlled release and spatially defined gene expression. As regulatory frameworks adapt, more gene-modified cell and tissue products are entering early-stage trials, suggesting a shift toward curative and adaptive solutions for complex diseases.
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Will be updated soon...
Vasiliki E Kalodimou, European University-Cyprus Ltd, Cyprus
Title : Will be updated soon...
Nagy Habib, Imperial College London, United Kingdom
Title : Will be updated soon...
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, United Kingdom
Title : Advanced 3D tissue models: Pioneering tools for investigating health and disease
Lucie Bacakova, Institute of Physiology of the Czech Academy of Sciences, Czech Republic
Title : Developing iPSC-derived 3D Outer Blood-Retinal Barrier Disease Models of Choroideremia for Gene Therapy Evaluation
Aradhana Kasimsetty, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), United States